Interstitial Lung Disease Associated with Chronic Nitrofurantoin Use
Main Article Content
Abstract
Introduction: Since 2011, nitrofurantoin has been reconsidered as a first-line treatment, but it can cause rare pulmonary and liver toxicity. Chronic use can lead to interstitial lung disease (ILD). The case presented highlights the suspicion of ILD in patients with respiratory symptoms after prolonged nitrofurantoin use.
Case presentation: A 64-year-old woman receiving nitrofurantoin long-term developed severe pulmonary symptoms. After ruling out infections and autoimmune diseases, pulmonary toxicity was suspected. Treatment produced significant improvement, and she was discharged, continuing therapy and discontinuing nitrofurantoin.
Conclusion: Nitrofurantoin toxicity is underreported in Mexico. Despite being safe, prolonged use can cause serious effects, so regular follow-up is essential.
Article Details
This work is licensed under a Creative Commons Attribution 4.0 International License.
References
I. Queiroz Marcelino, L. ., & Adrian Estrin, M. . (2025). Nitrofurantoin: analysis of its long-term effects and contraindications. Interamerican Journal of Health Sciences, 5, 267. https://doi.org/10.59471/ijhsc2025267
II. Akopyan K, Zafar R, Faruqi I. History Is the Key to Diagnosis: A Case of Nitrofurantoin-Induced Interstitial Lung Disease. Cureus. 2024 Mar 13; e56097. Available in: http://dx.doi.org/10.7759/cureus.56097
III. View of Long term nitrofurantoin induced interstitial lung disease: a case series and literature review. (s. f.). https://www.mattioli1885journals.com/index.php/sarcoidosis/article/view/13827/11734
IV. SoperUncomplicated Cystitis and Pyelonephritis (UTI). https://www.idsociety.org/practice-guideline/uncomplicated-cystitis-and-pyelonephritis-uti/
V. Maredia, N. N., Fanning, M. J., Christie, A. L., Prokesch, B. C., & Zimmern, P. E. (2020). Adverse effects of chronic nitrofurantoin therapy in women with recurrent urinary tract infections in an outpatient setting. World Journal Of Urology, 39(7), 2597-2603. https://doi.org/10.1007/s00345-020-03464-w
VI. Gallas, J. M. M., González, Á. O., & Ortiz, J. F. (2015). Toxicidad pulmonar crónica por nitrofurantoína. Medicina General y de Familia, 4(3), 85-88. https://doi.org/10.1016/j.mgyf.2015.08.004
VII. Suliman AM, Alamin MA, Irfan Ul Haq. Nitrofurantoin-Induced Lung Injury: A Reminder of an Overlooked Threat. Cureus. 2023 Sep 5;
VIII. Geerts, A. F. J., Eppenga, W. L., Heerdink, R., Derijks, H. J., Wensing, M. J. P., Egberts, T. C. G., & De Smet, P. A. G. M. (2013). Ineffectiveness and adverse events of nitrofurantoin in women with urinary tract infection and renal impairment in primary care. European Journal Of Clinical Pharmacology, 69(9), 1701-1707. https://doi.org/10.1007/s00228-013-1520-x
IX. Naureen, S., Hart, S., Jawad, N., Kennan, N., & Faruqi, S. (2023). Long term nitrofurantoin induced interstitial lung disease: a case series and literature review. PubMed, 40(4), e2023050. https://doi.org/10.36141/svdld.v40i4.13827
X. Chin, A. j., Rashid S., Gharibeh, T. R., Kibbe P. S., Wynbrandt J. H., (2020) Interstitial Lung Disease Secondary to Long-Term Nitrofurantoin Use; e-ISSN 1941- 5923, DOI: 10.12659/AJCR.920386
XI. Viejo, M. Á. N., Montes, A. F., Montes, J. V., Gómez-Román, J. J., Ibarbia, C. G., & Hernández, J. L. H. (2009). Rapid Resolution of Nitrofurantoin-Induced Interstitial Lung Disease. Archivos de Bronconeumología, 45(7), 352-355. https://doi.org/10.1016/s15792129(09)72437-1
XII. Flaherty, K. R., Toews, G. B., Lynch, J. P., Kazerooni, E. A., Gross, B. H., Strawderman, R. L., Hariharan, K., Flint, A., & Martinez, F. J. (2001). Steroids in idiopathic pulmonary fibrosis: a prospective assessment of adverse reactions, response to therapy, and survival∗∗Access the “Journal Club” discussion of this paper at http://www.elsevier.com/locate/ajmselect/. The American Journal Of Medicine, 110(4), 278-282. https://doi.org/10.1016/s0002-9343(00)00711-7
XIII. Um, S. H., Abuzgaia, A., & Rieder, M. (2023). Comparison of the Liverpool Causality Assessment Tool vs. the Naranjo Scale for predicting the likelihood of an adverse drug reaction: A retrospective cohort study. British Journal Of Clinical Pharmacology, 89(8), 2407-2412. https://doi.org/10.1111/bcp.15704
XIV. Mankikian, J., Caille, A., Reynaud-Gaubert, M., Agier, M., Bermudez, J., Bonniaud, P., Borie, R., Brillet, P., Cadranel, J., Court-Fortune, I., Crestani, B., Debray, M., Gomez, E., Gondouin, A., Hirschi-Santelmo, S., Israel-Biet, D., Jouneau, S., Juvin, K., Leger, J., . . . Marchand-Adam, S. (2023). Rituximab and mycophenolate mofetil combination in patients with interstitial lung disease (EVER-ILD): a double-blind, randomised, placebo-controlled trial. European Respiratory Journal, 61(6), 2202071. https://doi.org/10.1183/13993003.02071-2022
XV. Wells, A. U., & Hirani, N. (2008). Interstitial lung disease guideline. Thorax, 63(Supplement 5), v1-v58. https://doi.org/10.1136/thx.2008.101691
XVI. Wells, A. U., Flaherty, K. R., Brown, K. K., Inoue, Y., Devaraj, A., Richeldi, L., Moua, T., Crestani, B., Wuyts, W. A., Stowasser, S., Quaresma, M., Goeldner, R., Schlenker-Herceg, R., Kolb, M., Abe, S., Aburto, M., Acosta, O., Andrews, C., Antin-Ozerkis, D., . . . Ziora, D. (2020). Nintedanib in patients with progressive fibrosing interstitial lung diseases—subgroup analyses by interstitial lung disease diagnosis in the INBUILD trial: a randomised, double-blind, placebo-controlled, parallel-group trial. The Lancet Respiratory Medicine, 8(5), 453-460. https://doi.org/10.1016/s2213-2600(20)30036-9
XVII. Algoritmo de causalidad de Naranjo | Grupo de Farmacología Clinica. (s. f.). https://clinpharmacolgroup.es/algoritmo-de-causalidad-de-naranjo/
XVIII. Kondoh, Y., Taniguchi, H., Yokoi, T., Nishiyama, O., Ohishi, T., Kato, T., Suzuki, K., & Suzuki, R. (2005). Cyclophosphamide and low-dose prednisolone in idiopathic pulmonary fibrosis and fibrosing nonspecific interstitial pneumonia. European Respiratory Journal, 25(3), 528-533. https://doi.org/10.1183/09031936.05.00071004